Mineralocorticoid receptor antagonism in diabetes reduces albuminuria by preserving the glomerular endothelial glycocalyx
JCI Insight · 2023
DOI: 10.1172/jci.insight.154164 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JCI Insight, 2023. Verfasst von Michael Crompton und 19 weiteren Autor:innen. Beteiligte Einrichtung: Bristol Renal, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Diabetes Mellitus. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Heart Foundation, Medical Research Council, Kidney Research UK.
Themen: Diabetes mellitus
Abstract (Originalsprache)
The glomerular endothelial glycocalyx (GEnGlx) forms the first part of the glomerular filtration barrier. Previously, we showed that mineralocorticoid receptor (MR) activation caused GEnGlx damage and albuminuria. In this study, we investigated whether MR antagonism could limit albuminuria in diabetes and studied the site of action. Streptozotocin-induced diabetic Wistar rats developed albuminuria, increased glomerular albumin permeability (P s’ alb ), and increased glomerular matrix metalloproteinase (MMP) activity with corresponding GEnGlx loss. MR antagonism prevented albuminuria progression, restored P s’ alb , preserved GEnGlx, and reduced MMP activity. Enzymatic degradation of the GEnGlx negated the benefits of MR antagonism, confirming their dependence on GEnGlx integrity. Exposing human glomerular endothelial cells (GEnC) to diabetic conditions in vitro increased MMPs and caused glycocalyx damage. Amelioration of these effects confirmed a direct effect of MR antagonism on GEnC. To confirm relevance to human disease, we used a potentially novel confocal imaging method to show loss of GEnGlx in renal biopsy specimens from patients with diabetic nephropathy (DN). In addition, patients with DN randomized to receive an MR antagonist had reduced urinary MMP2 activity and albuminuria compared with placebo and baseline levels. Taken together, our work suggests that MR antagonists reduce MMP activity and thereby preserve GEnGlx, resulting in reduced glomerular permeability and albuminuria in diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bristol Renal, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
- Pathology Department, Southmead Hospital, Bristol, United Kingdom.
- School of Physiology, Pharmacology & Neuroscience, University of Bristol, Bristol, United Kingdom.
- Division of Nephrology, Dialysis and Transplantation, Department of Emergency and Organ Transplantation, Aldo Moro University of Bari, Bari, Italy.
- Department of Clinical Pharmacology, University Medical Center Groningen, University of Groningen, The Netherlands.
- Department of Clinical Sciences, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Förderung
- British Heart Foundation
- Medical Research Council
- Kidney Research UK
- Diabetes UK
- Horizon 2020
- See list below
Zitieren
APA
Crompton, M., Ferguson, J. K., Ramnath, R. D., Onions, K. L., Ogier, A. S., Gamez, M., Down, C. J., Skinner, L., Wong, K. H., Dixon, L. K., Sutak, J., Harper, S. J., Pontrelli, P., Gesualdo, L., Heerspink, H. L., Toto, R. D., Welsh, G. I., Foster, R. R., Satchell, S. C., & Butler, M. J. (2023). Mineralocorticoid receptor antagonism in diabetes reduces albuminuria by preserving the glomerular endothelial glycocalyx. JCI Insight. https://doi.org/10.1172/jci.insight.154164
Vancouver
Crompton M, Ferguson JK, Ramnath RD, Onions KL, Ogier AS, Gamez M, et al. Mineralocorticoid receptor antagonism in diabetes reduces albuminuria by preserving the glomerular endothelial glycocalyx. JCI Insight. 2023. doi:10.1172/jci.insight.154164
BibTeX
@article{Crompton2023,
author = {Crompton, Michael and Ferguson, Joanne K and Ramnath, Raina D and Onions, Karen L and Ogier, Anna S and Gamez, Monica and Down, Colin J and Skinner, Laura and Wong, Kitty H and Dixon, Lauren K and Sutak, Judit and Harper, Steven J and Pontrelli, Paola and Gesualdo, Loreto and Heerspink, Hiddo L and Toto, Robert D and Welsh, Gavin I and Foster, Rebecca R and Satchell, Simon C and Butler, Matthew J},
title = {Mineralocorticoid receptor antagonism in diabetes reduces albuminuria by preserving the glomerular endothelial glycocalyx},
journal = {JCI Insight},
year = {2023},
doi = {10.1172/jci.insight.154164}
}
EUVIMED